Finance
Pharmaceutical company reports first quarter financial results
Published in Medical Letter on the CDC and FDA, June 5th, 2005
During this period, the company recorded $5.5 million in product shipments of the company's lead product, FACTIVE (gemifloxacin mesylate) tablets, U.S. Food and Drug Administration (FDA)-approved for the treatment of acute bacterial exacerbations of chronic bronchitis (AECB) and mild to moderate community-acquired pneumonia (CAP).
Net of the impact from introductory promotional programs, the company recorded $3.9 million in product revenue for the first quarter of 2005. First quarter product revenues include the recognition of $390,000...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Chickenpox Vaccine
Failure to get catch-up vaccinations causes varicella outbreak - Ebola Vaccine
CD8-mediated protection against Ebola infection is perforin dependent - Environmental Health
Organophosphorus pesticide exposure assessed by biomonitoring - Environmental Health
Urinary levels of bisphenol A and 4-nonylphenol in humans measured - Heart Disease Risk Factors
Trends in heart disease risk factors according to BMI reported - Addiction Medicine
Admissions for drug treatment up for older adults - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
